Incidentaloma differential diagnosis: Difference between revisions

Jump to navigation Jump to search
Line 113: Line 113:


=== Differential diagnosis of Cushing's disease from other diseases ===
=== Differential diagnosis of Cushing's disease from other diseases ===
The table below summarizes the findings that differentiate Cushing's disease from other conditions that may cause [[Hypertension|hypertensio]]<nowiki/>n, [[hyperandrogenism]], and [[obesity]]. Facial [[plethora]], [[skin changes]], [[osteoporosis]], [[nephrolithiasis]] and [[neuropsychiatric]] conditions should raise the concern for Cushing's syndrome.<ref name="pmid11253984">{{cite journal |vauthors=Boscaro M, Barzon L, Fallo F, Sonino N |title=Cushing's syndrome |journal=Lancet |volume=357 |issue=9258 |pages=783–91 |year=2001 |pmid=11253984 |doi=10.1016/S0140-6736(00)04172-6 |url=}}</ref><ref name="pmid11571938">{{cite journal |vauthors=Findling JW, Raff H |title=Diagnosis and differential diagnosis of Cushing's syndrome |journal=Endocrinol. Metab. Clin. North Am. |volume=30 |issue=3 |pages=729–47 |year=2001 |pmid=11571938 |doi= |url=}}</ref><ref name="pmid9793762">{{cite journal |vauthors=Newell-Price J, Trainer P, Besser M, Grossman A |title=The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states |journal=Endocr. Rev. |volume=19 |issue=5 |pages=647–72 |year=1998 |pmid=9793762 |doi=10.1210/edrv.19.5.0346 |url=}}</ref><ref name="urlHow Is Metabolic Syndrome Diagnosed? - NHLBI, NIH">{{cite web |url=https://www.nhlbi.nih.gov/health/health-topics/topics/ms/diagnosis |title=How Is Metabolic Syndrome Diagnosed? - NHLBI, NIH |format= |work= |accessdate=}}</ref>
The table below summarizes the findings that differentiate [[Cushing's disease]] from other conditions that may cause [[Hypertension|hypertensio]]<nowiki/>n, [[hyperandrogenism]], and [[obesity]]. Facial [[plethora]], [[skin changes]], [[osteoporosis]], [[nephrolithiasis]] and [[neuropsychiatric]] conditions should raise the concern for [[Cushing's syndrome]].<ref name="pmid11253984">{{cite journal |vauthors=Boscaro M, Barzon L, Fallo F, Sonino N |title=Cushing's syndrome |journal=Lancet |volume=357 |issue=9258 |pages=783–91 |year=2001 |pmid=11253984 |doi=10.1016/S0140-6736(00)04172-6 |url=}}</ref><ref name="pmid11571938">{{cite journal |vauthors=Findling JW, Raff H |title=Diagnosis and differential diagnosis of Cushing's syndrome |journal=Endocrinol. Metab. Clin. North Am. |volume=30 |issue=3 |pages=729–47 |year=2001 |pmid=11571938 |doi= |url=}}</ref><ref name="pmid9793762">{{cite journal |vauthors=Newell-Price J, Trainer P, Besser M, Grossman A |title=The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states |journal=Endocr. Rev. |volume=19 |issue=5 |pages=647–72 |year=1998 |pmid=9793762 |doi=10.1210/edrv.19.5.0346 |url=}}</ref><ref name="urlHow Is Metabolic Syndrome Diagnosed? - NHLBI, NIH">{{cite web |url=https://www.nhlbi.nih.gov/health/health-topics/topics/ms/diagnosis |title=How Is Metabolic Syndrome Diagnosed? - NHLBI, NIH |format= |work= |accessdate=}}</ref>
<br>
<br>
{| align="center"
{| align="center"
Line 142: Line 142:
*[[Kidney stone|Kidney stones]]
*[[Kidney stone|Kidney stones]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
*24-hour urine cortisol
*24-hour urine [[cortisol]]
*Midnight salivary cortisol
*Midnight salivary [[cortisol]]
*[[Dexamethasone Oral|Low dose dexamethasone]] challenge test
*[[Dexamethasone Oral|Low dose dexamethasone]] challenge test
*[[CRH]] stimulation
*[[CRH]] stimulation
*[[Dexamethasone Oral|High dose dexamethasone]] test
*[[Dexamethasone Oral|High dose dexamethasone]] test
*[[MRI|MRI brain]]
*[[MRI|MRI brain]]
*CT/MRI adrenals
*[[Computed tomography|CT]]/[[Magnetic resonance imaging|MRI]] adrenals


|-
|-
Line 164: Line 164:
*[[Oligomenorrhea]]/[[hypogonadism]]
*[[Oligomenorrhea]]/[[hypogonadism]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
*Urinary free cortisol
*[[Urinary system|Urinary]] free [[cortisol]]
*Midnight salivary cortisol
*Midnight salivary [[cortisol]]
*Low dose dexamethasone challenge test
*Low dose [[dexamethasone]] challenge test
*[[Glucose tolerance test]]
*[[Glucose tolerance test]]
*Loperamide test
*[[Loperamide]] test
|-
|-
| style="background:#DCDCDC;" align="center" |[[Metabolic syndrome X]]
| style="background:#DCDCDC;" align="center" |[[Metabolic syndrome X]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
*Familial/genetic
*[[Family|Familial]]/[[Genetics|genetic]]
*Obesity
*[[Obesity]]
*Insulin resistance
*[[Insulin]] resistance
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* [[Obesity]]
* [[Obesity]]
Line 200: Line 200:
|-
|-
| style="background:#DCDCDC;" align="center" | [[Pheochromocytoma]]
| style="background:#DCDCDC;" align="center" | [[Pheochromocytoma]]
|The symptoms of a pheochromocytoma are those of [[sympathetic nervous system]]<nowiki/>hyperactivity and include:<sup>[[Renal artery stenosis ultrasound#cite note-pmid23457117-1|[1]]]</sup>
|The symptoms of a [[pheochromocytoma]] are those of [[sympathetic nervous system]]<nowiki/>hyperactivity and include:<sup>[[Renal artery stenosis ultrasound#cite note-pmid23457117-1|[1]]]</sup>
* [[Palpitations]] (especially in [[epinephrine]] producing tumors)
* [[Palpitations]] (especially in [[epinephrine]] producing tumors)
* [[Anxiety]] 
* [[Anxiety]] 
Line 214: Line 214:
* '''High-risk patients''':  
* '''High-risk patients''':  
** [[Plasma]] fractionated [[Metanephrine|metanephrines]]  
** [[Plasma]] fractionated [[Metanephrine|metanephrines]]  
** 24-hour [[urinary]] fractionated [[Metanephrine|metanephrines]], catecholamines
** 24-hour [[urinary]] fractionated [[Metanephrine|metanephrines]], [[Catecholamine|catecholamines]]
** Imaging studies ([[CT scan]], [[Magnetic resonance imaging|MRI]] and  iodine-123-meta-iodobenzylguanidine or MIBG scintiscan)<sup>[[Renal artery stenosis ultrasound#cite note-pmid23457117-1|[1]]]</sup>
** Imaging studies ([[CT scan]], [[Magnetic resonance imaging|MRI]] and  iodine-123-meta-iodobenzylguanidine or MIBG scintiscan)<sup>[[Renal artery stenosis ultrasound#cite note-pmid23457117-1|[1]]]</sup>


Line 265: Line 265:
|Elevated [[blood pressure]], [[tachycardia]], and may be [[anxiety]] in a clinical setting but not in other settings<sup>[[Chronic hypertension differential diagnosis#cite note-pmid24107724-1|[1]]]</sup>
|Elevated [[blood pressure]], [[tachycardia]], and may be [[anxiety]] in a clinical setting but not in other settings<sup>[[Chronic hypertension differential diagnosis#cite note-pmid24107724-1|[1]]]</sup>
|
|
* Ambulatory blood pressure monitoring and patient self-measurement using a home [[blood pressure]] monitoring device are being increasingly used to differentiate patients with [[white coat hypertension]] from patients with true [[hypertension]].
* Ambulatory [[blood pressure]] monitoring and patient self-measurement using a home [[blood pressure]] monitoring device are being increasingly used to differentiate patients with [[white coat hypertension]] from patients with true [[hypertension]].
|-
|-
| style="background:#DCDCDC;" align="center" | [[Hyperthyroidism]]
| style="background:#DCDCDC;" align="center" | [[Hyperthyroidism]]
Line 283: Line 283:
* [[Systolic hypertension]]<ref name="pmid2045465">{{cite journal| author=Mintz G, Pizzarello R, Klein I| title=Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment. | journal=J Clin Endocrinol Metab | year= 1991 | volume= 73 | issue= 1 | pages= 146-50 | pmid=2045465 | doi=10.1210/jcem-73-1-146 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2045465  }}</ref>
* [[Systolic hypertension]]<ref name="pmid2045465">{{cite journal| author=Mintz G, Pizzarello R, Klein I| title=Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment. | journal=J Clin Endocrinol Metab | year= 1991 | volume= 73 | issue= 1 | pages= 146-50 | pmid=2045465 | doi=10.1210/jcem-73-1-146 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2045465  }}</ref>
|
|
* Low [[thyroid-stimulating hormone]] (TSH)
* Low [[thyroid-stimulating hormone]] ([[Thyroid-stimulating hormone|TSH]])
* High [[Thyroxine|free thyroxine]] (T4) concentration
* High [[Thyroxine|free thyroxine]] ([[T4]]) concentration
* High [[triiodothyronine]] (T3) concentration
* High [[triiodothyronine]] ([[Triiodothyronine|T3]]) concentration
|-
|-
| style="background:#DCDCDC;" align="center" | [[Renal artery stenosis|Renovascular hypertension]]
| style="background:#DCDCDC;" align="center" | [[Renal artery stenosis|Renovascular hypertension]]
Line 304: Line 304:
| style="background:#DCDCDC;" align="center" | [[Stroke]] and [[Lateral medullary syndrome|compression of lateral medulla]] ([[Lateral medullary syndrome]])
| style="background:#DCDCDC;" align="center" | [[Stroke]] and [[Lateral medullary syndrome|compression of lateral medulla]] ([[Lateral medullary syndrome]])
|
|
* Extensive unilateral infarction of the [[brain stem]] in the region of the [[nucleus tractus solitarius]] may result in partial [[Baroreflex|baroreflex dysfunction]], increased sympathetic activity, and neurogenic [[paroxysmal hypertension]].
* Extensive unilateral infarction of the [[brain stem]] in the region of the [[nucleus tractus solitarius]] may result in partial [[Baroreflex|baroreflex dysfunction]], increased sympathetic activity, and [[neurogenic]] [[paroxysmal hypertension]].
* [[Blurred vision]] or [[diplopia]]
* [[Blurred vision]] or [[diplopia]]
* Weakness of [[Bulbar palsy|bulbar muscles]]
* Weakness of [[Bulbar palsy|bulbar muscles]]
Line 315: Line 315:
* Ipsilateral decreased pain and temperature sensation in the face
* Ipsilateral decreased pain and temperature sensation in the face
* The [[corneal reflex]] is usually reduced in the [[ipsilateral]] eye
* The [[corneal reflex]] is usually reduced in the [[ipsilateral]] eye
* Contralateral loss of pain and thermal sensation involving the body and limbs
* Contralateral loss of [[pain]] and thermal sensation involving the body and limbs
|
|
* [[Computed tomography|CT]] shows mass compressing [[Lateral medullary syndrome|lateral medulla]] or infarction in the same area
* [[Computed tomography|CT]] shows mass compressing [[Lateral medullary syndrome|lateral medulla]] or infarction in the same area
Line 323: Line 323:
* [[Tonic-clonic seizure]]:
* [[Tonic-clonic seizure]]:
** Repetitive twitches of arm and legs
** Repetitive twitches of arm and legs
** Tongue bitting
** [[Tongue]] bitting
** [[Loss of consciousness]]
** [[Loss of consciousness]]
** Symptoms occur suddenly and may persist
** Symptoms occur suddenly and may persist
Line 342: Line 342:
* Physical examination is important when [[central nervous system infection]] or hemorrhage are diagnostic possibilities
* Physical examination is important when [[central nervous system infection]] or hemorrhage are diagnostic possibilities


* A tongue bite or laceration in [[Tonic-clonic seizure|generalized tonic-clonic seizure]]<ref name="pmid23041172">{{cite journal|author=Brigo F, Storti M, Lochner P, Tezzon F, Fiaschi A, Bongiovanni LG et al.|title=Tongue biting in epileptic seizures and psychogenic events: an evidence-based perspective.|journal=Epilepsy Behav|year=2012|volume=25|issue=2|pages=251-5|pmid=23041172|doi=10.1016/j.yebeh.2012.06.020|pmc=|url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23041172}}</ref>
* A [[tongue]] bite or laceration in [[Tonic-clonic seizure|generalized tonic-clonic seizure]]<ref name="pmid23041172">{{cite journal|author=Brigo F, Storti M, Lochner P, Tezzon F, Fiaschi A, Bongiovanni LG et al.|title=Tongue biting in epileptic seizures and psychogenic events: an evidence-based perspective.|journal=Epilepsy Behav|year=2012|volume=25|issue=2|pages=251-5|pmid=23041172|doi=10.1016/j.yebeh.2012.06.020|pmc=|url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23041172}}</ref>
|
|
* Abnormal [[electroencephalography]]: a positive test without a clinical presentation is called a [[Subclinical seizure|sub-clinical seizure]].<ref name="pmid21205698">{{cite journal|author=Fountain NB, Van Ness PC, Swain-Eng R, Tonn S, Bever CT, American Academy of Neurology Epilepsy Measure Development Panel and the American Medical Association-Convened Physician Consortium for Performance Improvement Independent Measure Development Process|title=Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology.|journal=Neurology|year=2011|volume=76|issue=1|pages=94-9|pmid=21205698|doi=10.1212/WNL.0b013e318203e9d1|pmc=|url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21205698}}</ref>
* Abnormal [[electroencephalography]]: a positive test without a clinical presentation is called a [[Subclinical seizure|sub-clinical seizure]].<ref name="pmid21205698">{{cite journal|author=Fountain NB, Van Ness PC, Swain-Eng R, Tonn S, Bever CT, American Academy of Neurology Epilepsy Measure Development Panel and the American Medical Association-Convened Physician Consortium for Performance Improvement Independent Measure Development Process|title=Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology.|journal=Neurology|year=2011|volume=76|issue=1|pages=94-9|pmid=21205698|doi=10.1212/WNL.0b013e318203e9d1|pmc=|url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21205698}}</ref>
* [[Lumbar puncture]] is useful to exclude acute [[central nervous system infections]].
* [[Lumbar puncture]] is useful to exclude acute [[central nervous system infections]].
* A neuroimaging study should be performed in all adults with a first seizure to evaluate structural brain abnormalities. [[Magnetic resonance imaging]] is preferred over [[computed tomography]].
* A neuro-imaging study should be performed in all adults with a first [[seizure]] to evaluate structural [[brain]] abnormalities. [[Magnetic resonance imaging]] is preferred over [[computed tomography]].
|-
|-
| style="background:#DCDCDC;" align="center" |[[Carcinoid syndrome]]
| style="background:#DCDCDC;" align="center" |[[Carcinoid syndrome]]
|[[Hypertensive crisis]] occurs with [[malignant carcinoid syndrome]]<ref name="pmid7969229">{{cite journal| author=Warner RR, Mani S, Profeta J, Grunstein E| title=Octreotide treatment of carcinoid hypertensive crisis. | journal=Mt Sinai J Med | year= 1994 | volume= 61 | issue= 4 | pages= 349-55 | pmid=7969229 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7969229  }}</ref>. Symptoms include:
|[[Hypertensive crisis]] occurs with [[malignant carcinoid syndrome]]<ref name="pmid7969229">{{cite journal| author=Warner RR, Mani S, Profeta J, Grunstein E| title=Octreotide treatment of carcinoid hypertensive crisis. | journal=Mt Sinai J Med | year= 1994 | volume= 61 | issue= 4 | pages= 349-55 | pmid=7969229 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7969229  }}</ref>.  
Symptoms include:
* Severe [[chest]] pain
* Severe [[chest]] pain
* Severe [[headache]]
* Severe [[headache]]
Line 397: Line 398:
** Poor [[coordination]]
** Poor [[coordination]]
** [[Focal neurologic signs]]
** [[Focal neurologic signs]]
** [[Headache]]<nowiki/>s awakening the patient at nigt<sup>[[Migraine CT#cite note-3|[3]]][[Migraine CT#cite note-4|[4]]]</sup>
** [[Headache]]<nowiki/>s awakening the patient at night<sup>[[Migraine CT#cite note-3|[3]]][[Migraine CT#cite note-4|[4]]]</sup>
* Atypical [[aura]]
* Atypical [[aura]]
* Sudden onset
* Sudden onset

Revision as of 15:40, 7 November 2017

Incidentaloma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Incidentaloma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Incidentaloma differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Incidentaloma differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Incidentaloma differential diagnosis

CDC on Incidentaloma differential diagnosis

Incidentaloma differential diagnosis in the news

Blogs on Incidentaloma differential diagnosis

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Incidentaloma differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]

Overview

Adrenal incidentaloma must be differentiated from other diseases that cause adrenal masses such as adrenal adenoma, adrenocortical carcinoma, Cushing's syndrome, pheochromocytoma, and metastasis.

Differentiating different causese of Incidentaloma

Differential Diagnosis Clinical picture Imagings Laboratory tests
Adrenal adenoma
  • Round and homogeneous density, smooth contour and sharp margination
  • Diameter less than 4 cm, unilateral location
  • Low unenhanced CT attenuation values (<10 HU)
  • Rapid contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of more than 50 percent)
  • Isointensity with liver on both T1 and T2 weighted MRI sequences
  • Chemical shift: evidence of lipid on MRI
Adrenocortical carcinoma
  • Irregular shape
  • Inhomogeneous density because of central areas of low attenuation due to tumor necrosis
  • Tumor calcification
  • Diameter usually > 4 cm
  • Unilateral location
  • High unenhanced CT attenuation values (>20 HU)
  • Inhomogeneous enhancement on CT with intravenous contrast
  • Delay in contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of less than 50 percent)
  • Hypointensity compared with liver on T1 weighted MRI and high to intermediate signal intensity on T2 weighted MRI
  • High standardized uptake value (SUV) on FDG-PET-CT study
  • Evidence of local invasion or metastases
Cushing's syndrome
  • Imaging may show mass if presents
Pheochromocytoma
  • Increased attenuation on nonenhanced CT ( > 20 HU)
  • Increased mass vascularity
  • Delay in contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of less than 50 percent)
  • High signal intensity on T2 weighted MRI
  • Cystic and hemorrhagic changes
  • Variable size and may be bilateral
Adrenal metastasis
    • Irregular shape and inhomogeneous nature
    • Tendency to be bilateral
    • High unenhanced CT attenuation values ( > 20 HU) and enhancement with intravenous contrast on CT
    • Delay in contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of less than 50 percent)
    • Iso-intensity or slightly less intense than the liver on T1 weighted MRI and high to intermediate signal intensity on T2 weighted MRI (representing an increased water content)
    • Elevated standardized uptake value on FDG-PET scan

Differential diagnosis of Cushing's disease from other diseases

The table below summarizes the findings that differentiate Cushing's disease from other conditions that may cause hypertension, hyperandrogenism, and obesity. Facial plethora, skin changes, osteoporosis, nephrolithiasis and neuropsychiatric conditions should raise the concern for Cushing's syndrome.[1][2][3][4]

Conditions Causes Associated features Diagnostic approach
Cushing's syndrome
Pseudo-Cushing's syndrome
Metabolic syndrome X

Differentiating pheochromocytoma from other diseases

Pheochromocytoma must be differentiated from other causes of paroxysmal hypertension. The differentials include:

Disease Symptoms Signs Investigations
Pheochromocytoma The symptoms of a pheochromocytoma are those of sympathetic nervous systemhyperactivity and include:[1]
Pseudopheochromocytoma (idiopathic)[5][6][7][8] Paroxysmal activation of the sympathetic system causing:
Panic attacks

Laboratory studies that can exclude medical disorders other than panic disorder include:

Labile hypertension (White coat hypertension) Elevated blood pressure, tachycardia, and may be anxiety in a clinical setting but not in other settings[1]
Hyperthyroidism
Renovascular hypertension
Stroke and compression of lateral medulla (Lateral medullary syndrome)
  • Difficulty sitting upright without support
  • Hypotonia of the ipsilateral arm
  • Ipsilateral decreased pain and temperature sensation in the face
  • The corneal reflex is usually reduced in the ipsilateral eye
  • Contralateral loss of pain and thermal sensation involving the body and limbs
Seizures According to type; it may be focal or generalized, clinical or subclinical:[11]
  • Tonic-clonic seizure:
    • Repetitive twitches of arm and legs
    • Tongue bitting
    • Loss of consciousness
    • Symptoms occur suddenly and may persist
    • Muscle tension or tightening that causes twisting of the body, head, arms, or legs
    • Amnesia
    • Mood changes (fear, panic, or laughter)
    • Change in sensation of the skin over the arm, leg, or trunk
    • Vision changes and light flashes
    • Hallucinations
    • Tasting a bitter or metallic flavor
  • Complex partial seizure:
    • Confused or dazed and
    • Not be able to respond to questions or direction
  • Absence seizure:
    • Rapid blinking
    • Few seconds of staring into space
Carcinoid syndrome Hypertensive crisis occurs with malignant carcinoid syndrome[14].

Symptoms include:

Migraine headaches
  • Prodrome:
  • Pain phase
CT is indicated in patients with:[1][2]

CT is not indicated in:

Drugs Sympathomimetic drugs that can induce symptoms simulating pheochromocytoma include:
Baroreflex failure[22]
  • Baroreflex failure patients show a normal or even an increased pressor response to cold-pressor and handgrip testing. These responses are attenuated in patients with autonomic failure.
  • Neck CT scan

References

  1. Boscaro M, Barzon L, Fallo F, Sonino N (2001). "Cushing's syndrome". Lancet. 357 (9258): 783–91. doi:10.1016/S0140-6736(00)04172-6. PMID 11253984.
  2. Findling JW, Raff H (2001). "Diagnosis and differential diagnosis of Cushing's syndrome". Endocrinol. Metab. Clin. North Am. 30 (3): 729–47. PMID 11571938.
  3. Newell-Price J, Trainer P, Besser M, Grossman A (1998). "The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states". Endocr. Rev. 19 (5): 647–72. doi:10.1210/edrv.19.5.0346. PMID 9793762.
  4. "How Is Metabolic Syndrome Diagnosed? - NHLBI, NIH".
  5. Mann SJ (1999). "Severe paroxysmal hypertension (pseudopheochromocytoma): understanding the cause and treatment". Arch Intern Med. 159 (7): 670–4. PMID 10218745.
  6. Mann SJ (1999). "Severe paroxysmal hypertension (pseudopheochromocytoma): understanding the cause and treatment". Arch Intern Med. 159 (7): 670–4. PMID 10218745.
  7. Mann SJ (1996). "Severe paroxysmal hypertension. An automatic syndrome and its relationship to repressed emotions". Psychosomatics. 37 (5): 444–50. doi:10.1016/S0033-3182(96)71532-3. PMID 8824124.
  8. Sharabi Y, Goldstein DS, Bentho O, Saleem A, Pechnik S, Geraci MF; et al. (2007). "Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma". J Hypertens. 25 (11): 2286–95. doi:10.1097/HJH.0b013e3282ef5fac. PMID 17921824.
  9. Iglesias P, Acosta M, Sánchez R, Fernández-Reyes MJ, Mon C, Díez JJ (2005). "Ambulatory blood pressure monitoring in patients with hyperthyroidism before and after control of thyroid function". Clin Endocrinol (Oxf). 63 (1): 66–72. doi:10.1111/j.1365-2265.2005.02301.x. PMID 15963064.
  10. Mintz G, Pizzarello R, Klein I (1991). "Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment". J Clin Endocrinol Metab. 73 (1): 146–50. doi:10.1210/jcem-73-1-146. PMID 2045465.
  11. 11.0 11.1 Mintz G, Pizzarello R, Klein I (1991). "Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment". J Clin Endocrinol Metab. 73 (1): 146–50. doi:10.1210/jcem-73-1-146. PMID 2045465.
  12. Brigo F, Storti M, Lochner P, Tezzon F, Fiaschi A, Bongiovanni LG; et al. (2012). "Tongue biting in epileptic seizures and psychogenic events: an evidence-based perspective". Epilepsy Behav. 25 (2): 251–5. doi:10.1016/j.yebeh.2012.06.020. PMID 23041172.
  13. Fountain NB, Van Ness PC, Swain-Eng R, Tonn S, Bever CT, American Academy of Neurology Epilepsy Measure Development Panel and the American Medical Association-Convened Physician Consortium for Performance Improvement Independent Measure Development Process (2011). "Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology". Neurology. 76 (1): 94–9. doi:10.1212/WNL.0b013e318203e9d1. PMID 21205698.
  14. Warner RR, Mani S, Profeta J, Grunstein E (1994). "Octreotide treatment of carcinoid hypertensive crisis". Mt Sinai J Med. 61 (4): 349–55. PMID 7969229.
  15. Sjöblom SM (1988). "Clinical presentation and prognosis of gastrointestinal carcinoid tumours". Scand J Gastroenterol. 23 (7): 779–87. PMID 3227292.
  16. Feldman JM (1986). "Urinary serotonin in the diagnosis of carcinoid tumors". Clin Chem. 32 (5): 840–4. PMID 2421946.
  17. Eriksson B, Arnberg H, Oberg K, Hellman U, Lundqvist G, Wernstedt C; et al. (1990). "A polyclonal antiserum against chromogranin A and B--a new sensitive marker for neuroendocrine tumours". Acta Endocrinol (Copenh). 122 (2): 145–55. PMID 2316306.
  18. Sundin A, Vullierme MP, Kaltsas G, Plöckinger U, Mallorca Consensus Conference participants. European Neuroendocrine Tumor Society (2009). "ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations". Neuroendocrinology. 90 (2): 167–83. doi:10.1159/000184855. PMID 19077417.
  19. Kelman L (2004). "The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs". Headache. 44 (9): 865–72. doi:10.1111/j.1526-4610.2004.04168.x. PMID 15447695.
  20. Krentz AJ, Mikhail S, Cantrell P, Hill GM (2001). "Drug Points: Pseudophaeochromocytoma syndrome associated with clozapine". BMJ. 322 (7296): 1213. PMC 31620. PMID 11358774.
  21. Kuchel O (1985). "Pseudopheochromocytoma". Hypertension. 7 (1): 151–8. PMID 3980057.
  22. Robertson D, Hollister AS, Biaggioni I, Netterville JL, Mosqueda-Garcia R, Robertson RM (1993). "The diagnosis and treatment of baroreflex failure". N Engl J Med. 329 (20): 1449–55. doi:10.1056/NEJM199311113292003. PMID 8413455.
  23. 23.0 23.1 Zar T, Peixoto AJ (2008). "Paroxysmal hypertension due to baroreflex failure". Kidney Int. 74 (1): 126–31. doi:10.1038/ki.2008.30. PMID 18322544.

Template:WH Template:WS